The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell

N Gao1, Y D Hu, X Y Cao

  • 1Department of Radiotherapy, Cancer Institute and Cancer Hospital, Shanghai Medical University, Shanghai 200032, P.R. China.

Insights

The p14ARF gene, a potential lung cancer suppressor, inhibits tumor growth and enhances radiosensitivity in lung cancer cells. Restoring p14ARF function may fortify p53 activity, increasing treatment effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The INK4A/CDKN2A/MTS1 gene locus at 9p21 is frequently inactivated in lung cancers, targeting the p16INK4a protein.
  • The p14ARF transcript, an alternative splice form of this locus, also shows alterations in lung cancers and regulates p53, suggesting a tumor suppressor role.

Purpose of the Study:

  • To investigate the candidacy of p14ARF as a lung cancer suppressor gene.
  • To evaluate the impact of p14ARF on the radiosensitivity of lung cancer cells.

Main Methods:

  • Wild-type p14ARF gene transfection into four lung cancer cell lines with varying genetic backgrounds (INK4A, p53, RB status).
  • Assessment of cell growth inhibition, cell cycle redistribution, and radiosensitivity post-transfection.
  • Analysis of radiation-induced apoptosis and p53 function.

Main Results:

  • p14ARF transfection induced significant growth inhibition in all wild-type p53 cell lines, irrespective of INK4A/ARF and RB status.
  • Radiosensitivity increased in p14ARF-deficient cell lines following p14ARF gene transfer, potentially due to cell cycle redistribution.
  • Enhanced radiation-induced apoptosis was observed in one cell line, suggesting a fortified p53 function.

Conclusions:

  • p14ARF acts as a lung cancer suppressor gene, inhibiting cell proliferation.
  • Restoration of p14ARF enhances lung cancer cell radiosensitivity, possibly through cell cycle modulation and p53 pathway activation.
  • p14ARF may represent a therapeutic target for improving lung cancer treatment efficacy.